Literature DB >> 22635163

COX-2 inhibitors in prostate cancer treatment--hold your horses?

Ada S Cheung1, Mathis Grossmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22635163      PMCID： PMC3720074          DOI： 10.1038/aja.2012.51

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  15 in total

1.  A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer.

Authors:  Rosebud O Roberts; Debra J Jacobson; Cynthia J Girman; Thomas Rhodes; Michael M Lieber; Steven J Jacobsen
Journal:  Mayo Clin Proc       Date:  2002-03       Impact factor: 7.616

2.  Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.

Authors:  S Gupta; M Srivastava; N Ahmad; D G Bostwick; H Mukhtar
Journal:  Prostate       Date:  2000-01       Impact factor: 4.104

3.  Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.

Authors:  Rachel S Midgley; Christopher C McConkey; Elaine C Johnstone; Janet A Dunn; Justine L Smith; Simon A Grumett; Patrick Julier; Claire Iveson; Yoko Yanagisawa; Bryan Warren; Michael J Langman; David J Kerr
Journal:  J Clin Oncol       Date:  2010-09-13       Impact factor: 44.544

4.  The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.

Authors:  A L Hsu; T T Ching; D S Wang; X Song; V M Rangnekar; C S Chen
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

5.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.

Authors:  C E Eberhart; R J Coffey; A Radhika; F M Giardiello; S Ferrenbach; R N DuBois
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

Review 6.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

Authors:  Peter M Rothwell; Jacqueline F Price; F Gerald R Fowkes; Alberto Zanchetti; Maria Carla Roncaglioni; Gianni Tognoni; Robert Lee; Jill F F Belch; Michelle Wilson; Ziyah Mehta; Tom W Meade
Journal:  Lancet       Date:  2012-03-21       Impact factor: 79.321

7.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.

Authors:  Peter M Rothwell; Michelle Wilson; Jacqueline F Price; Jill F F Belch; Tom W Meade; Ziyah Mehta
Journal:  Lancet       Date:  2012-03-21       Impact factor: 79.321

8.  Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study.

Authors:  Salaheddin M Mahmud; Eduardo L Franco; Donna Turner; Robert W Platt; Patricia Beck; David Skarsgard; Jon Tonita; Colin Sharpe; Armen G Aprikian
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

9.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321

10.  Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Malcolm D Mason; Noel W Clarke; John Anderson; David P Dearnaley; John Dwyer; Gordana Jovic; Alastair W S Ritchie; J Martin Russell; Karen Sanders; George N Thalmann; Gianfilippo Bertelli; Alison J Birtle; Joe M O'Sullivan; Andrew Protheroe; Denise Sheehan; Narayanan Srihari; Mahesh K B Parmar
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316
View more
  1 in total

1.  Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.

Authors:  C-J Ko; S-W Lan; Y-C Lu; T-S Cheng; P-F Lai; C-H Tsai; T-W Hsu; H-Y Lin; H-Y Shyu; S-R Wu; H-H Lin; P-W Hsiao; C-H Chen; H-P Huang; M-S Lee
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.